Answers are grounded in this paper and cite their sources.
Cochrane Review evaluates anaemia treatments in myelodysplastic syndromes, suggesting potential benefits and risks.
OBJECTIVES: This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To evaluate the benefits and harms of both supportive and disease-modifying drug treatments for anaemia in people with MDS, comparing them to each other, or the standard of care with or without placebo.
No takes yet. Share an insight, caveat, or question.
Mo et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: